Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND: AP1189 plus methotrexate in early rheumatoid arthritis
2022-001828-15Phase 2Completed
- Sponsor
- SynAct Pharma AB
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing AP1189 100 mg + methotrexate with Placebo + methotrexate (2 arms). Primary endpoints: Overall efficacy and safety at 12 weeks and Comparison of AP1189 100 mg versus placebo. Started Sep 2022; status: completed.
02
Drugs
resomelagon
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-001828-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001828-15.